The Oil & Gas Journal, first published in 1902, is the world's most widely read petroleum industry publication. OGJ delivers international oil and gas industry news; analysis of issues and events; practical technology for design, operation, and maintenance of oil and gas operations; and important statistics on energy markets and industry activity.

OGJ is edited to meet the needs of engineers, geoscientists, managers, and executives throughout the oil and gas industry. It is part of Endeavor Business Media, Nashville, Tenn., which also publishes Offshore Magazine.

Endeavor Business Media’s Petroleum Group also produces targeted e-Newsletters; hosts global conferences and exhibitions, seminars, and forums; and publishes directories, technical books, print and electronic databases, surveys, and maps.

Additional Information

Website & Technical Help

For help with subscription purchases or refunds, or trouble logging into the paid subscription content on www.ogj.com, please contact Customer Service at [email protected] or call 1-847-559-7598.

For more customer service information, please click here.

Amicus Therapeutics Announces Participation at the World Muscle Society Annual Congress 2024

PRINCETON, N.J., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that three posters highlighting its development program for Pompe disease will be included at the 29th Annual Congress of the World Muscle Society being held October 8-12, 2024 in Prague, Czechia.

Poster Session: Pompe Disease

Abstract Title: Cipaglucosidase alfa + miglustat in late-onset Pompe disease: two non-ambulatory patients switching from high-dose, high-frequency alglucosidase alfa (Poster #657P)

  • Presenter: Barry J. Byrne, MD, PhD, University of Florida, Gainesville, FL, U.S.A.
  • Poster Session: Friday, October 11, 3:45 – 4:45 p.m. CET
  • Location: Forum Hall, The Prague Congress Centre

Abstract Title: Post-baseline outcomes of the UK Early Access to Medicines Scheme registry for cipaglucosidase alfa plus miglustat in late-onset Pompe disease (Poster #670P)

  • Presenter: Mark Roberts, MD, Salford Royal NHS Foundation Trust, Greater Manchester Neurosciences Centre, Manchester, U.K.
  • Poster Session: Friday, October 11, 3:45 – 4:45 p.m. CET
  • Location: Forum Hall, The Prague Congress Centre

Abstract Title: Miglustat: a first-in-class enzyme stabilizer for late-onset Pompe disease (Poster #671P)

  • Presenter: Tahseen Mozaffar, MD, Department of Neurology, University of California, Irvine, CA, U.S.A.
  • Poster Session: Friday, October 11, 3:45 – 4:45 p.m. CET
  • Location: Forum Hall, The Prague Congress Centre

For more information on the WMS 2024 Annual Congress, please visit www.wms2024.com

About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information please visit the company’s website at www.amicusrx.com, and follow on X and LinkedIn.

CONTACTS:

Investors:
Amicus Therapeutics
Andrew Faughnan
Vice President, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809

Media:
Amicus Therapeutics
Diana Moore
Head of Global Corporate Communications
dmoore@amicusrx.com
(609) 662-5079

FOLD–G


Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.